The goal of the MD Anderson/Rice Cancer Nanotech T32 Fellowship is to train scientists who will transfer the great promise of nanotechnology in to clinical reality. This novel training program educates future leaders in the broad field of nanotechnology with specific interests in cancer-related applications, who are keenly aware of the needs and demands of clinical environment as well as of major challenges of translational research.
This is a two-tiered program: the Predoctoral Program provides mentorship, training, and funding for 2 years to students who have been accepted into the Ph.D. program in bioengineering, chemistry, or applied physics at Rice University and have completed 1 or 2 years of their didactic coursework; and the Postdoctoral Program provides a 2-year fellowship to recent Ph.D. awardees with training in physical science, chemistry, or bioengineering with a demonstrated background and interest in nanotechnology. Holders of an M.D. degree will be eligible for the program if they show a strong interest in translational cancer nanotechnology research.
This training program includes multidisciplinary, hands-on coursework, seminar experiences, and multidisciplinary mentorship of translational research projects.
Shared laboratory facilities and equipment provide program fellows with an outstanding research environment that combines state-of-the-art instrumentation, facilities for animal research, and vast opportunities to be an integral part of clinical trials.
The program includes a total of 25 faculty mentors (18) and co-mentors (7) from MD Anderson Cancer Center (8 mentors and 6 co-mentors) and Rice University (10 mentors and 1 co-mentor).
Each fellow will be co-mentored by two program faculty - one from MD Anderson Cancer Center and one from Rice University. Detailed information can also be found on the T32 Program Flyer. Program eligibility: per program requirement fellows "must be a citizen or a noncitizen national of the United States or have been lawfully admitted for permanent residence at the time of appointment."
T32 Predoctoral Fellow Emily Reiser Evans
receives Outstanding Poster Award at the
NIH Alliance for Nanotechnology in
Cancer 2016 Meeting